These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32001171)

  • 1. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project.
    de Leeuw FA; van der Flier WM; Tijms BM; Scheltens P; Mendes VM; Manadas B; Bierau J; van Wijk N; van den Heuvel EGHM; Mohajeri MH; Teunissen CE; Kester MI
    J Am Med Dir Assoc; 2020 Oct; 21(10):1513.e1-1513.e17. PubMed ID: 32001171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project.
    de Leeuw FA; Tijms BM; Doorduijn AS; Hendriksen HMA; van de Rest O; de van der Schueren MAE; Visser M; van den Heuvel EGHM; van Wijk N; Bierau J; van Berckel BN; Scheltens P; Kester MI; van der Flier WM; Teunissen CE
    Alzheimers Dement (Amst); 2020; 12(1):e12120. PubMed ID: 33392381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
    Stark M; Wolfsgruber S; Kleineidam L; Frommann I; Altenstein S; Bartels C; Brosseron F; Buerger K; Burow L; Butryn M; Ewers M; Fliessbach K; Gabelin T; Glanz W; Goerss D; Gref D; Hansen N; Heneka MT; Hinderer P; Incesoy EI; Janowitz D; Kilimann I; Kimmich O; Laske C; Munk MH; Perneczky R; Peters O; Preis L; Priller J; Rauchmann BS; Rostamzadeh A; Roy-Kluth N; Sanzenbacher C; Schneider A; Schott BH; Spottke A; Spruth EJ; Teipel S; Vogt IR; Wiltfang J; Duzel E; Jessen F; Wagner M
    Neurology; 2023 Nov; 101(21):e2185-e2196. PubMed ID: 37821235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis.
    Aye S; Bouteloup V; Tate A; Wimo A; Handels R; Jean D; Winblad B; Jönsson L
    Alzheimers Res Ther; 2023 Nov; 15(1):200. PubMed ID: 37968734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project.
    Doorduijn AS; de van der Schueren MAE; van de Rest O; de Leeuw FA; Hendriksen HMA; Teunissen CE; Scheltens P; van der Flier WM; Visser M
    J Am Med Dir Assoc; 2023 May; 24(5):638-644.e1. PubMed ID: 33239240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment.
    Thomas KR; Edmonds EC; Eppig J; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2018; 64(1):195-204. PubMed ID: 29865077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of Alzheimer's Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review.
    Scarth M; Rissanen I; Scholten RJPM; Geerlings MI
    J Alzheimers Dis; 2021; 83(3):1089-1111. PubMed ID: 34397412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine - A predictor for five year-mortality in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia.
    Futschek IE; Schernhammer E; Haslacher H; Stögmann E; Lehrner J
    Exp Gerontol; 2023 Feb; 172():112045. PubMed ID: 36509298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
    Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
    J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary intakes and biomarker patterns of folate, vitamin B
    An Y; Feng L; Zhang X; Wang Y; Wang Y; Tao L; Qin Z; Xiao R
    Clin Epigenetics; 2019 Oct; 11(1):139. PubMed ID: 31601260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.